Therapy News and Research

RSS

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Myriad Genetics, Inc. today presented results from a pivotal clinical validation study of the Myriad myPath- Melanoma test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Ill.

2 Jun 2014

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

From Quest Diagnostics 2 Jun 2014

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report.

31 May 2014

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β).

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy.

31 May 2014

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral and cancer mutations are to be reported in a poster presentation titled "Detection of novel HPV mutations and chromosomal number imbalance (CNI) in oropharyngeal and laryngeal cancer using next-generation sequencing (NGS)" (Abstract #6072) at the American Society of Clinical Oncology Annual Meeting (ASCO 2014) being held from May 30 through June 3, 2014 in Chicago.

31 May 2014

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today the presentation of clinical data from studies demonstrating the potential utility of comprehensive molecular profiling in guiding treatment of patients with gynecologic malignancies, including breast cancers and ovarian cancer.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Raised systolic and diastolic blood pressures may have different effects on different types of cardiovascular diseases and at different ages, according to new research involving 1.25 million patients from primary care practices in England published in a special themed issue of The Lancet.

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Palliative care can reduce pain and other distressing symptoms

When three-year-old Rachel was diagnosed with cancer, it was one of the worst days of her mother's life. Tests, medications, surgery—young Rachel's life turned upside down.

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

On Friday, April 18th PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc.

31 May 2014

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of  lung cancer cases and the development of 29 more different conditions.

31 May 2014

Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.

31 May 2014

Use of chemotherapy before surgery to remove ovarian cancer has increased dramatically

The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

31 May 2014

Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

Among men treated for prostate cancer, those who received radiation therapy were more likely to develop bladder or rectal cancer, according to a new study from the University of Michigan Comprehensive Cancer Center.

31 May 2014

Therapy News and Research

Pivotal clinical validation study of Myriad myPath Melanoma test presented at ASCO 2014

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Investigational drug for advanced bladder cancer shows promise for treatment of certain tumor types

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Systolic, diastolic blood pressures may have different effects on different types of cardiovascular diseases

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Palliative care can reduce pain and other distressing symptoms

ArQule to present tivantinib clinical trial data at ASCO 2014

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

Researchers develop virtual platform that measures level of addiction of smokers

Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Use of chemotherapy before surgery to remove ovarian cancer has increased dramatically

Men who receive radiation therapy for prostate cancer more likely to develop rectal cancer

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News